Novartis announced positive results from two Phase 3 studies of its B-cell depleting antibody, ianalumab, in Sjögren’s syndrome and primary immune thrombocytopenia (ITP). Both trials achieved their primary endpoints, demonstrating statistically significant improvements in disease activity and prolonged time to treatment failure respectively. These are the first global phase 3 successes in Sjögren’s, a disease with limited treatments, positioning ianalumab as a leading targeted therapy candidate. Regulatory submissions are anticipated.